This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



vandetanib (Caprelsa®)


Reference No. 427

Publication date:
25/09/2014


Last review date:
13/12/2017

Appraisal information

vandetanib (Caprelsa®) 100 mg film-coated tablet
vandetanib (Caprelsa®) 300 mg film-coated tablet


Company: Genzyme Therapeutics
BNF category: Malignant disease and immunosupression
NMG meeting date: 23/07/2014
AWMSG meeting date: 03/09/2014
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 2514
Ratification by Welsh Government: 24/09/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA550) NICE GUIDANCE ISSUED OCTOBER 2018 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download